Page 111 - Read Online

Keung et al. J Transl Genet Genom 2019;3:8. I https://doi.org/10.20517/jtgg.2019.03 Page 9 of 9

46. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in
vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
47. Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, et al. Pleomorphic liposarcoma: Clinical observations and molecular variables. Cancer
2011;117:5359-69.
48. Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, et al. Pleomorphic liposarcoma: clinicopathologic analysis of 57
cases. Am J Surg Pathol 2004;28:1257-67.
49. Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary
liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006;24:381-91.
50. Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and
follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26:601-16.
51. Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology 2014;64:38-52.
52. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, et al. Functional copy-number alterations in cancer. PLoS One 2008;3:e3179.
53. Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, et al. Role of chemotherapy in dedifferentiated liposarcoma of the
retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 2017;7:1-8.
54. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for
retroperitoneal liposarcoma. Ann Surg 2003;238:358-70. discussion 370-1.
55. Dalal KM, Antonescu CR, Singer S. Diagnosis and management of lipomatous tumors. J Surg Oncol 2008;97:298-313.
56. Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of
chemotherapy and survival. Ann Oncol 2012;23:1601-7.
57. Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer 2016;18:604-10.
58. McGovern Y, Zhou CD, Jones RL. Systemic therapy in metastatic or unresectable well-differentiated/dedifferentiated liposarcoma. Front
Oncol 2017;7:292.
59. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic
liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J
Clin Oncol 2016;34:786-93.
60. Ratan R, Patel SR. Trabectedin and eribulin: where do they fit in the management of soft tissue sarcoma? Curr Treat Options Oncol
2017;18:1-9.
61. Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, et al. Efficacy and tolerability of trabectedin in elderly patients with sarcoma:
subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or
leiomyosarcoma. Ann Oncol 2018;29:1995-2002.
62. Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a
subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 2017;35:3433-9.
63. Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, et al. Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer
Ther 2017;17:717-23.
64. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, et al. Eribulin versus dacarbazine in previously treated patients with advanced
liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-37.
65. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007;12:999-1006.
66. Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol 2018;36:125-
35.
67. Wilky BA, Jones RL, Keedy VL. The current landscape of early drug development for patients with sarcoma. Am Soc Clin Oncol Educ B
[Internet] 2017;37:807-10. Available from: http://meetinglibrary.asco.org/content/174701-199 [Last accessed on 25 Apr 2019]
68. Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and Old) approach to treatment of soft tissue and bone sarcomas.
Oncologist 2018;23:71-83.
69. Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, et al. Results of a prospective phase 2 study of pazopanib in patients with
advanced intermediate-grade or high-grade liposarcoma. Cancer 2017;123:4640-7.
70. Keung EZ, Wargo JA. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2018;
71. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg 1891;14:199-220.
72. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma
(SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18:1493-501.
73. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, et al. Nivolumab with or without ipilimumab treatment for metastatic
sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018;19:416-26.
74. D’Angelo SP, Druta M, Liebner DA, Schuetze S, Somaiah N, et al. Pilot study of NY-ESO-1 c259 T cells in advanced myxoid/round cell
liposarcoma. J Clin Oncol 2018;36:3005. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3005. [Last accessed
on 25 Apr 2019]